US biopharma firm Amgen to acquire Horizon Therapeutics for $28 bn
New York (AFP) - US biopharmaceutical firm Amgen said Monday it has reached agreement to acquire Horizon Therapeutics, which specializes in medicine for rare and auto-immune diseases, for $27.8 billion. The California-based company said it will pay cash to the tune of $116.50 a share in Horizon Therapeutics, a 20 percent premium over Horizon's closing price Friday on Wall Street, in what would be the biggest deal of the year in the health sector. The bid will be financed through a bank lending facility. Founded in 2005, Horizon Therapeutics develops and markets drugs for rare, auto-immune and...